Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07548671
PHASE3
Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA
Sponsor: Peking Union Medical College Hospital
View on ClinicalTrials.gov
Summary
This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).
Official title: Efficacy and Safety of Enarodustat Combined With Cyclosporine Versus Cyclosporine Monotherapy in the Treatment of Newly Diagnosed TD-NSAA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04
Completion Date
2029-12
Last Updated
2026-04-23
Healthy Volunteers
No
Interventions
DRUG
Enarodustat
Enarodustat 8mg qd
DRUG
Cyclosporine (CsA)
CsA 3-5mg/kg/d, trough concentration 100-200ng/ml